BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kushner T, Dieterich D, Saberi B. Direct-acting antiviral treatment for patients with hepatocellular carcinoma. Current Opinion in Gastroenterology 2018;34:132-9. [DOI: 10.1097/mog.0000000000000431] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Yen YH, Chen CH, Hung CH, Wang JH, Lu SN, Kee KM, Hu TH. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data. PLoS One 2019;14:e0222605. [PMID: 31581209 DOI: 10.1371/journal.pone.0222605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Syed T, Fazili J Dr, Ali IA, Zhao D, Hughes D, Mahmood S MD. Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals. Cureus 2018;10:e2843. [PMID: 30280052 DOI: 10.7759/cureus.2843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020;20:220-30. [PMID: 31437349 DOI: 10.1111/ajt.15576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]